This was a randomized, phase 2 clinical trial that compared the effects of temozolomide alone with those of temozolomide in combination with capecitabine. It included 144 patients.
Combination of capecitabine and temozolomide produced longer progression-free survival rates, higher response rates, and longer overall survival rates than temozolomide alone
.
Advertisement
In addition, deficiency of the DNA repair enzyme methylguanine methyltransferase (MGMT) in the tumor tissue, was found to be associated with increased responses.
“This clinical trial is practice-changing and the combination of capecitabine and temozolomide should be included as a standard treatment option for patients with advanced pancreatic NETs,” said Kunz.
“In addition, MGMT testing can be considered for select patients receiving temozolomide for whom the response is a primary goal of treatment. However, testing is not recommended for routine use as confirmatory studies are needed.”
The findings are part of the ECOG-ACRIN E2211 trial, conducted through the National Cancer Institute and the National Clinical Trial Network.
Source: Medindia
